29 Objective 30 Identification of germline mutation in patients with apparently sporadic phaeochromocytomas 31 and paragangliomas is crucial. Clinical indicators, which include young age, bilateral or 32 multifocal, extra-adrenal, malignant or recurrent tumours, predict the likelihood of harbouring 33 germline mutation in Caucasian subjects. However, data on the prevalence of germline 34 mutation, as well as the applicability of these clinical indicators in Chinese, are lacking. 35 36 Design and methods 37 We conducted a cross-sectional study at a single endocrine tertiary referral centre in Hong 38 Kong. Subjects with phaeochromocytomas and paragangliomas were evaluated for the 39 presence of germline mutations involving 10 susceptibility genes, which included NF1, RET, 40 VHL, SDHA, SDHB, SDHC, SDHD, TMEM 127, MAX and FH genes. Clinical indicators 41 were assessed for their association with the presence of germline mutations. 42 43 Results 44 Germline mutations, two being novel, were found in 24.4% of the 41 Chinese subjects 45 recruited and 11.4% among those with apparently sporadic presentation. The increasing 46 number of the afore-mentioned clinical indicators significantly correlated with the likelihood 47 129 130 Materials and methods
of harbouring germline mutation in one of the 10 susceptibility genes. (r = 0.757, p = 0.026). 
159
Among a total of 60 subjects with PPGLs being followed up at our clinics, 11 known 160 asymptomatic germline mutations carriers were excluded, as they were family members of 161 probands with familial diseases (10 subjects with MEN2, and 1 subject with VHL disease).
162
Of the remaining 49 subjects, 8 refused to participate. Therefore, 41 unrelated eligible 163 subjects with PPGLs were finally enrolled into our study. 
203
In our cohort of 41 subjects, 9 subjects were found to harbour germline mutations and 1 204 subject had NF1, which translated into a prevalence of 24.4% for hereditary PPGL. On the 205 other hand, 6 of these 10 subjects had syndromic features suggestive of hereditary disease at 206 disease presentation. Therefore, 35 subjects had PPGL with apparently sporadic presentation, 207 and the prevalence rate of germline mutations was 11.4% (4 of 35 subjects).
209
Among the 9 mutations identified on sequencing, 7 were located on the RET gene, 1 on the 210 SDHB gene and 1 on the SDHD gene. Both the deletion mutation in the SDHB gene and the 211 insertion mutation on the SDHD gene were novel pathogenic variants that had not been 212 previously reported (Table 1) . A sequence variant was also found on exon 2 of the TMEM127 213 (c.53C>T) gene in 3 subjects, including the subject with an SDHB germline mutation. All 3 214 subjects were heterozygous for this sequence variant. However, in-silico analyses suggested 215 that the sequence variant was not associated with any change in protein structure.
216
Furthermore, screening of 100 healthy controls also revealed 2 subjects with the same 217 heterozygous variants, yielding a minor allelic frequency of 1%. Hence, this sequence variant 218 in TMEM127 gene was likely a polymorphism rather than a pathogenic mutation.
220
Of the 35 subjects (18 men and 17 women) with apparently sporadic PPGL in our study 221 cohort, 27 and 8 had phaeochromocytoma and paraganglioma respectively. Among those 222 paragangliomas, 1 was head and neck paraganglioma, 3 were in the abdomen and 4 were in 223 the bladder. Their mean age of diagnosis was 45 ± 13 years. Other biochemical and tumour 224 characteristics are summarized in Table 2 . About 77% of the tumours were larger than 3cm, 225 28.6% were either multifocal or bilateral tumours, and 89.3% showed avidity on MIBG scan.
226
The prevalence of malignancy was 11.4% and the recurrence rate was 22.9% over a median 227 follow-up of 5 years.
229
In our study, the frequency of germline mutations in subjects with syndromic presentation (4 230 subjects with a personal history of medullary thyroid carcinoma or oral mucosal neuromas, 1 231 subject with a family history of PPGL and 1 subject with phenotypic features of NF1) was 232 100%. However, in those subjects with apparently sporadic presentation, we found that only 233 "age of disease onset younger than 45 years old" (p = 0.023) and having "bilateral or 234 multifocal tumours" (100% versus 19% in subjects without mutations, p <0.004) were 235 statistically significant clinical indicators of presence of germline mutations (Table 3) .
236
Furthermore, we have shown that, with an increasing number of these clinical indicators, the 237 subjects were more likely to harbour germline mutations (r = 0.757, p = 0.026; Gamma test).
238
In addition, with the ROC curve, we demonstrated that in those subjects with an apparently 239 sporadic presentation of PPGL, the presence of 2 or more of the clinical indicators provided 240 the optimal cut-off to initiate genetic testing, with a 100% sensitivity of picking up germline 241 mutation in 1 of the 10 susceptibility genes of PPGL, coupled with a specificity of 77.4%.
242
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